Spectrum Health Advanced Technology Laboratories are proud to announce that the first and only FDA-approved blood test for colorectal cancer screening is now available at Spectrum Health Molecular Diagnostics Laboratory. The Epi proColon Septin 9 Methylation Analysis test is indicated to screen adults of either sex, 50 years or older, defined as average risk for colorectal cancer (CRC), who have been offered and have a history of not completing CRC screening.
New Test FY16
The new orderable for the Gram stain for BV and yeast is available
The Gram stain for bacterial vaginosis (BV) and yeast is considered the gold standard for the diagnosis of various vaginal infections. The Gram stain utilizes the Nugent scoring method to evaluate the ratios of Lactobacillus, Gardnerella vaginalis, Mobiluncus, and Atopobium vaginae. Accurate diagnosis of BV relies upon both the increase in abundance of specific urogenital pathogens (such as Gardnerella) as well as the concordant decrease in the amount of otherwise protective “usual flora” (Lactobacillus). In addition to scoring the abundance of these organisms, the Gram stain may also be used to quantify yeast making suspected contributions to BV.
Effective June 1, 2016, Malaria testing will be updated. Recommended first line testing for suspected malaria is called Malaria Rapid Screen which is a combination of a rapid BinaxNow test in Hematology and a blood smear review in Microbiology. The BinaxNow test has a reported sensitivity of 97.7% and specificity of 94.2% for detection of P. falciparum species if a patient has a parasitemia level of over 5000 parasites/uL; sensitivity is lower for other malaria species. The BinaxNow test is not reported to cross react with babesia species. BinaxNow testing will be available for all shifts in Hematology at the Spectrum Health Regional Laboratory. The specimen requirements are unchanged from previous malaria testing. Previous test “Malaria Smear for Protozoa” will be discontinued.